Known targets — ChEMBL curated mechanism
MTORPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5
The experimentally established mechanism targets of Dactolisib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR known ✓ | P42345 | 17/20 | 0.83 |
| ▸ | PIK3CA known ✓ | P42336 | 14/20 | 0.83 |
| ▸ | PIK3CD known ✓ | O00329 | 8/20 | 0.83 |
| ▸ | PIK3CG known ✓ | P48736 | 6/20 | 0.83 |
| ▸ | PIK3CB known ✓ | P42338 | 5/20 | 0.83 |
| ▸ | PIK3R1 known ✓ | P27986 | 1/20 | 0.83 |
| ▸ | PIK3R5 known ✓ | Q8WYR1 | 1/20 | 0.83 |
| ▸ | PRKDC | P78527 | 3/20 | 0.83 |
| ▸ | ATM | Q13315 | 3/20 | 0.83 |
| ▸ | PIK3C2A | O00443 | 2/20 | 0.83 |
| ▸ | PIK3C2B | O00750 | 2/20 | 0.83 |
| ▸ | ATR | Q13535 | 2/20 | 0.83 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.83 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.83 |
| ▸ | CSF1R | P07333 | 1/20 | 0.83 |
| ▸ | MET | P08581 | 1/20 | 0.83 |
| ▸ | LTK | P29376 | 1/20 | 0.83 |
| ▸ | CDK7 | P50613 | 1/20 | 0.83 |
| ▸ | NEK2 | P51955 | 1/20 | 0.83 |
| ▸ | JAK3 | P52333 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dactolisib SCHEMBL30587353 | 1.00 | MTOR (0.83) | MTORPIK3CAPIK3CDPIK3CGPIK3CB | |
| SCHEMBL994756 | 0.94 | MTOR (0.73) | MTORPIK3CAPIK3CDPIK3CGPIK3CB | |
| SCHEMBL994760 | 0.93 | MTOR (0.70) | MTORPIK3CAPIK3CDPIK3CGPIK3CB | |
| SCHEMBL995934 | 0.91 | MTOR (0.68) | MTORPIK3CAPIK3CDPIK3CGPIK3CB | |
| Dactolisib SCHEMBL143623 | 0.91 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3CGPIK3CB | |
| Dactolisib SCHEMBL2424463 | 0.91 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3CGPIK3CB | |
| Dactolisib SCHEMBL29370906 | 0.91 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3CGPIK3CB | |
| Dactolisib SCHEMBL30186162 | 0.91 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3CGPIK3CB | |
| SCHEMBL994357 | 0.91 | MTOR (0.68) | MTORPIK3CAPIK3CDPIK3CGPIK3CB | |
| SCHEMBL994361 | 0.89 | PIK3CA (0.70) | MTORPIK3CAPIK3CDPIK3CGPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4605376-A1 | ISOQUINOLINE DERIVATIVES AS PROTEIN DEGRADERS, E7 DEGRADERS, ANTIVIRALS, TUMOR THERAPEUTICS AND IMMUNE SUPPRESSIVES | RDP Pharma AG (CH) | 2025-08-27 | — | — | EP | claimed |
| CN-120202190-A | Isoquinoline derivatives as protein degrading agents, E7 degrading agents, antiviral agents, tumor therapeutic agents and immunosuppressants | RDP制药股份公司 | 2025-06-24 | — | — | CN | claimed |
| EP-4548977-A2 | NOVEL ISOQUINOLINES AS PROTEIN DEGRADERS, E7 DEGRADERS, ANTIVIRALS, TUMOR THERAPEUTICS AND IMMUNE SUPPRESSIVES | RDP Pharma AG (CH) | 2025-05-07 | — | — | EP | claimed |
| US-20240294876-A1 | METHODS FOR THE EXPANSION OF HUMAN GRANULOCYTE-MACROPHAGE PROGENITORS AND APPLICATIONS THEREOF | UNIV SOUTHERN CALIFORNIA (US) | 2024-09-05 | — | — | US | claimed |
| WO-2024083802-A1 | ISOQUINOLINE DERIVATIVES AS PROTEIN DEGRADERS, E7 DEGRADERS, ANTIVIRALS, TUMOR THERAPEUTICS AND IMMUNE SUPPRESSIVES | VALDOSPAN GMBH (AT) | 2024-04-25 | — | — | WO | claimed |
| US-20240115571-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | RGCM SA LLC, AS PURCHASER AGENT | 2024-04-11 | — | — | US | claimed |
| EP-4341386-A2 | METHODS FOR THE EXPANSION OF HUMAN GRANULOCYTEMACROPHAGE PROGENITORS AND APPLICATIONS THEREOF | University of Southern California (US) | 2024-03-27 | — | — | EP | claimed |
| CN-117729923-A | Combination therapy for the treatment of abnormal cell growth | 维瑞斯特姆股份有限公司 | 2024-03-19 | — | — | CN | claimed |
| EP-4322949-A1 | ISOQUINOLINE DERIVATIVES FOR USE AS ANTIVIRAL AND ANTITUMOUR AGENTS | RDP Pharma AG (CH) | 2024-02-21 | — | — | EP | claimed |
| EP-4288057-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | Verastem, Inc. (US) | 2023-12-13 | — | — | EP | claimed |
| WO-2022245977-A2 | METHODS FOR THE EXPANSION OF HUMAN GRANULOCYTEMACROPHAGE PROGENITORS AND APPLICATIONS THEREOF | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2022-11-24 | — | — | WO | claimed |
| WO-2022219157-A1 | ISOQUINOLINE DERIVATIVES FOR USE AS ANTIVIRAL AND ANTITUMOUR AGENTS | VALDOSPAN GMBH (AT) | 2022-10-20 | — | — | WO | claimed |
| WO-2022170060-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | VERASTEM, INC. (US) | 2022-08-11 | — | — | WO | claimed |
| US-8431592-B2 | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase inhibitors | NOVARTIS AG (CH) | 2013-04-30 | — | — | US | claimed |
| US-7667039-B2 | 1,3-dihydro-imidazo [4,5-C] quinolin-2-ones as lipid kinase inhibitors | NOVARTIS AG (CH) | 2010-02-23 | — | — | US | claimed |
| US-20080194579-A1 | 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | claimed |
| US-20260053799-A1 | COMPOUNDS FOR TREATING CANCER | EVEXTA BIO (FR) | 2026-02-26 | — | — | US | disclosed |
| US-20250387350-A1 | BIOMARKERS OF METAP2 INHIBITORS AND APPLICATIONS THEREOF | SYNDEVRX INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-1888578-A2 | IMIDAZOQUINOLINES AS LIPID KINASE INHIBITORS | Novartis AG (CH) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006122806-A2 | 1,3-DIHYDRO-IMIDAZO [4,5-C] QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115571-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | DUSP6, SOS1, DUSP1 | MTOR 25/4885PIK3CA 99/4885PIK3CD 271/4885 |
| US-20260053799-A1 | COMPOUNDS FOR TREATING CANCER | NCOA1, AR, ESR2 | MTOR 1508/4885PIK3CA 2362/4885PIK3CD 3863/4885 |
| US-20250387350-A1 | BIOMARKERS OF METAP2 INHIBITORS AND APPLICATIONS THEREOF | METAP2, TGFB2, IGF2BP2 | MTOR 15/4885PIK3CA 455/4885PIK3CD 656/4885 |
| US-20080194579-A1 | 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors | PDPK1, PI4KA, PIP4K2A | MTOR 89/4885PIK3CA 8/4885PIK3CD 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.